Catalyst Pharmaceuticals Named Among Forbes 2022 America’s Best Small Companies
The Company Ranked 65th of More Than 1,000 Companies Assessed CORAL GABLES, Fla., March 08,…
News
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage…
GelStat Provides Corporate Update on Capital Restructuring
STUART, Fla., March 08, 2022 (GLOBE NEWSWIRE) — GelStat Corporation (“GelStat” or the “Company”) (OTCPink:…
Frontier Medicines Announces the Appointment of Monique Bobadilla as Chief People and Culture Officer
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Frontier Medicines Corporation, a precision…
Marrone Bio Innovations to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28 at 4:30 p.m. Eastern Time
RALEIGH, N.C., March 08, 2022 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII), an…
Achieve Life Sciences Announces Participation in March Investor Conferences
SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences,…
VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned
Phase 3 OVAL trial enrolled 409 patients globally at centers in the United States, Europe,…
X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the…
Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327
Highlights: Independent Safety Committee unanimously recommends cohort four (RECCE® 327 at 1,000mg) to commence; a…
Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis
With Growing Rate of Childhood Myopia, MIRA-4 Trial Supports a Potential Broader RM Label for…
Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company…
Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare
— Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives…
Cognition Therapeutics Announces Participation in March Investment Conferences
PURCHASE, N.Y., March 08, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical…
Adaptive Research and UBERDOC Announce Collaboration to Expand Clinical Trial Access to Physicians and Patients
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) — Adaptive Research, an integrated clinical trial site…
Enlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
Nes-Ziona, Israel, March 08, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022
DEER PARK, Ill., March 08, 2022 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an…
Ayala Pharmaceuticals, MD Anderson Cancer Center and the Adenoid Cystic Carcinoma Research Foundation Announce Initiation of Enrollment in Window of Opportunity Study of AL101 in Adenoid Cystic Carcinoma
Window of Opportunity Study is Evaluating AL101 Administered Prior to Surgery in Patients with Advanced,…
Science 37 to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022
RESEARCH TRIANGLE PARK, N.C., March 08, 2022 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
Media Release COPENHAGEN, Denmark; March 8, 2022 Genmab A/S (Nasdaq: GMAB) announced today that the…
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022
SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO;…